Investing in an ageing population
The world’s population is living longer than ever before. In 1995, the average global population life expectancy was 65. By 2025 this figure is expected to grow to 73. At the same time birth rates are declining, resulting in an ageing global population.
The world’s population is living longer than ever before. In 1995, the average global population life expectancy was 65. By 2025 this figure is expected to grow to 73. At the same time birth rates are declining, resulting in an ageing global population. It is expected that the world’s 65 and older demographic is expected to grow 18 times faster than the world’s under 15 demographic from 2010 to 2050.
Naturally there is increased demand projected for products and services from companies that cater to the ageing group’s health needs.
Key sectors include pharmaceuticals and biotech companies involved in the treatment of diseases related to ageing, healthcare services, medical products and devices and senior care facilities such as nursing homes and retirement communities .
Investors may take advantage of this trend by looking abroad for the bigger players in the field.
The Leveraged Margin Loan offers lending on a diverse range of global shares traded on leading international share markets, including those detailed below which are positioned to grow in line with an ageing population.
ABBV:US AbbVie Inc (NYSE)
Market Cap of $150bln as at 22/11/2017
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Covering autoimmune disease, testosterone replacement and Parkinson’s disease.
AMGN:US Amgen Inc (NASDAQ)
Market Cap of $123Bln as at 22/11/2017
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company’s products include treatment for osteoporosis in postmenopausal women, coronary artery disease, plaque psoriasis, rheumatoid arthritis, psoriatic arthritis and skeletal-related events prevention.
BDX:US Becton Dickinson and Co (NYSE)
Market cap of $51Bln as at 22/11/2017
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences.
BIIB:US Biogen Inc (NASDAQ)
Market Cap of $66Bln as at 22/11/2017
Biogen Inc. is a biopharmaceutical company which discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide.
BSX:US Boston Scientific Corp (NYSE)
Market cap of $39Bln as at 22/11/2017
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg.
FME:GR Fresenius Medical Care AG & Co KGaA (XETRA)
Market Cap of €25Bln as at 22/11/2017
Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company which provides dialysis care and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.
REGN:US Regeneron Pharmaceuticals Inc (NASDAQ)
Market Cap of $41Bln as at 22/11/2017
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company which discovers, invents, develops, manufactures, and commercialises medicines for the treatment of serious medical conditions worldwide. Its products include injections for the treatment of neovascular age-related macular degeneration.
SYK:US Stryker Corp (NYSE)
Market cap of $58Bln as at 22/11/2017
Stryker Corporation operates as a medical technology company through three segments: Orthopaedics; MedSurg; and Neurotechnology and Spine. The Orthopaedics segment offers implants for use in hip and knee joint replacements.
Visit our website for the complete list of international shares available under the Leveraged Margin Loan.
Like all investments, borrowing to buy financial products carries risk – gearing can magnify your gains, as well as your losses. If you have any questions, or would like to discuss your loan account, please contact your Relationship Manager or call Leveraged on 1300 307 807.
Gearing involves risk. It can magnify your returns, however it may also magnify your losses.
Leveraged Equities Limited (ABN 26 051 629 282 AFSL 360118) is a subsidiary of Bendigo and Adelaide Bank Limited (ABN 11 068 049 178 AFSL 237879).
Information is general advice only and doesn't take into account your personal objectives, financial situation, or needs. The views of the author may not represent the views of the broader Bendigo and Adelaide Bank Group of companies (“the Group”). This information must not be relied upon as a substitute for financial planning, legal, tax or other professional advice. You should consider whether or not the product is appropriate for you, read the relevant PDS and product guide available at www.leveraged.com.au, and consider seeking professional investment advice.
Examples are for illustration only and are not intended as recommendations and may not reflect actual outcomes. Past performance is not an indication of future performance. The information provided in this document has not been verified and may be subject to change. It is given in good faith and has been derived from sources believed to be accurate. Accordingly no representation or warranty, express or implied is made as to the fairness, accuracy, completeness or correction of the information and opinions contained in this article. To the maximum extent permitted by law, no entity in the Group, its agents or officers shall be liable for any loss or damage arising from the reliance upon, or use of the information contained in this article.